迪哲医药：公司肺癌领域多项研究成果在2025年世界肺癌大会（WCLC）上公布

Core Viewpoint - DIZHE Pharmaceutical (688192.SH) reported promising results for its self-developed lung cancer targeted drug, Shuwozhe®, and high-selectivity JAK1 inhibitor, Gaoruizhe®, at the 2025 World Lung Cancer Conference (WCLC) [1] Group 1: Clinical Research Findings - The latest results from the international multicenter registration clinical study "WUKONG1B" for Shuwozhe® were presented at the conference [1] - Shuwozhe® demonstrated a favorable benefit/risk ratio in the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations [1] - The overall response rate (ORR) for Shuwozhe® combined with Anlotinib in first-line treatment of EGFR-sensitive mutations with co-mutations in NSCLC was reported at 77.8%, with a disease control rate (DCR) of 100% [1]